Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Amyotrophic Lateral Sclerosis (ALS): Prevention & Risk Reduction: Understanding Sporadic vs. Familial Risk, Modifiable Lifestyle Factors, Environmental Safety, and Genetic Counseling

A neurology reference on sporadic versus familial ALS, smoking and occupational exposures, head trauma, the main ALS genes, genetic counselling and predictive testing, and recognizing early motor symptoms.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This brief does something most writing on ALS avoids: it states plainly at the top that there is no proven way to prevent the disease. That honesty is the most valuable thing in it, and we would keep it exactly as written. The notes below are one insurance point that is irreversible if got wrong, one piece of advice that does not transfer to this disease, and some updates.
  • GINA is cited without its limits, and the gap matters more here than almost anywhere. The Genetic Information Nondiscrimination Act prohibits discrimination in health insurance and employment. It does not cover life insurance, disability insurance or long-term care insurance. Genetic counsellors routinely advise arranging that cover before predictive testing, because the test result cannot be unlearned and the applications ask. Several states add protections, and they vary.
  • The guidance on who should be tested has changed and the brief reflects the older position. Testing is now offered to people diagnosed with ALS generally, not only those with a family history. The reasons are that recognized ALS genes are found in a proportion of apparently sporadic cases, that gene-targeted trials require knowing the genotype, and above all that tofersen, an antisense therapy approved for SOD1-associated ALS, makes a SOD1 result change treatment rather than only explain things.
  • The section on supporting brain and metabolic health is where this brief departs from the evidence. Balanced diet, exercise, sleep and cardiovascular health are good general advice and have not been shown to prevent ALS. More specifically, the usual direction reverses here: higher body mass index and higher cholesterol before onset are associated with lower ALS risk, and after diagnosis higher weight is associated with better survival, which is why nutritional management in ALS aims at maintaining or gaining weight. Presenting heart-healthy advice as neuroprotection implies a control that does not exist and quietly suggests the disease was avoidable.
  • Head trauma deserves its complications. The association is inconsistent across studies, and reverse causation is a genuine problem: early ALS causes weakness and falls, so injuries in the years before diagnosis may be a consequence rather than a cause. Protective headgear is sensible on its own merits.
  • Strenuous exercise and athletes are missing and are the live question in this area. Elite athletes, particularly footballers in several countries, show higher ALS rates in multiple studies, and genetic studies using Mendelian randomization suggest frequent strenuous exercise may raise risk, possibly only against certain genetic backgrounds. This is not a reason to avoid exercise, and it is a reason not to tell people that general fitness advice protects them.
  • The C9orf72 entry should carry its overlap with frontotemporal dementia. Families carrying it often contain both conditions, which is why a grandparent recorded as having had dementia may be relevant family history, and why cognitive and behavioural change is something these families should know to watch for.
  • Two additions to the counselling section: reproductive options including preimplantation genetic testing exist for people carrying a known variant and are best discussed before a pregnancy; and testing a child for an adult-onset condition is generally not done.
  • One addition on early symptoms, since the brief rightly emphasizes them. Twitching without weakness is extremely common, usually benign, and one of the commonest reasons people fear ALS. Weakness is the symptom that matters. Diagnostic delay in ALS averages around a year and costs access to trials, treatment and planning time, so asking directly for a neurology referral is reasonable.
  • Everything else in the brief is accurate: ALS as a progressive disease of motor neurons with no proven prevention, arising from interaction between genetic susceptibility and other factors over time; roughly 90 percent sporadic and 10 percent familial; consistent epidemiological evidence linking smoking and pack-years to higher risk; heavy metals, pesticides, solvents and electrical trauma studied as possible occupational risks with workplace controls and protective equipment as the response; C9orf72, SOD1, TARDBP and FUS as recognized genes with variable penetrance; genetic counselling for families with a strong history, covering predictive testing, emotional and insurance implications and presymptomatic research cohorts; and the early symptoms warranting prompt neurological evaluation.

Download the PDF

All source documents